Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
3 E Network Technology Group Limited announced the completion of the initial system-level architecture specification for its next-generation customized AI storage controller and preliminary validation of its core data flow algorithms through software simulation. This progress marks a key step in the development of hardware designed to overcome Inpu…
Adagene Inc. announced its financial results for the six months ended June 30, 2026, highlighting significant clinical advancements in its lead candidate muzastotug (ADG126), a masked anti-CTLA-4 antibody. The company reported encouraging efficacy and safety data in microsatellite stable colorectal cancer (MSS CRC) and hepatocellular carcinoma (HCC…
Xilio Therapeutics announced FDA clearance of its IND application for XTX501, a bispecific PD-1/masked IL-2 therapy targeting solid tumors. The company is advancing additional masked T cell engager programs with anticipated IND submissions in 2027. Q2 financials showed increased collaboration revenue and reduced net loss, with a strong cash runway …
Nexxen International Ltd. reported record second quarter 2026 financial results, with Contribution ex-TAC of $97.8 million and programmatic revenue of $95.2 million, reflecting double-digit year-over-year growth. The company achieved an all-time record for quarterly Connected TV (CTV) revenue, up 33% year-over-year. Nexxen advanced its AI technolog…
Nexxen announced key executive appointments including Chance Johnson as President, Kara Puccinelli as Chief Commercial Officer, and Kenneth Suh as Chief Business Officer to strengthen leadership as the company scales its AI-powered unified advertising platform. These appointments aim to enhance strategic client relationships, expand enterprise grow…
Arbutus Biopharma reported a solid financial position at the end of Q2 2026, including receipt of a $178 million settlement payment from Moderna. The company filed international patent enforcement lawsuits against Pfizer and BioNTech related to its lipid nanoparticle technology. It also obtained FDA Fast Track designation for imdusiran, its hepatit…
Altimmune, Inc. announced key advancements in its late-stage clinical program for pemvidutide, targeting metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company initiated a global Phase 3 PERFORMA trial in MASH, reported positive Phase 2 topline data in AUD, and co…
Rekor Systems announced that their GoSecure platform now includes patent-pending audio verification capabilities, applying cryptographic authentication to audio recordings. This extends their technology beyond video to meet growing demands from law enforcement, courts, financial institutions, and government agencies for verifiable and tamper-proof …
PolyPid Ltd. reports FDA acceptance with Priority Review for its NDA submission of D-PLEX100 aimed at preventing surgical site infections in abdominal colorectal surgeries. The FDA PDUFA goal date is set for November 28, 2026, ahead of prior guidance, with a potential commercial launch in early 2027 under an exclusive U.S. and Canada partnership wi…
BrainsWay Ltd. reported a strong second quarter 2026 with revenue increasing 35% year-over-year to $17.1 million, a more than doubling of adjusted EBITDA to $3.5 million, and record shipments of Deep TMS systems up 42%. The company raised its full-year 2026 revenue guidance to $68-$70 million and adjusted EBITDA to $13-$14 million, citing expanding…
Ming Shing Group Holdings Limited (NASDAQ: PMA), a Hong Kong-based company focused on wet trades works and graphene technology, announced entering into a stock purchase agreement to acquire Meals Through Seasons Limited, a company controlling MTHK which operates in organic agricultural supply chain, cold chain logistics, and product processing. The…
Unicycive Therapeutics announced its Q2 2026 financial results and provided a business update highlighting progress toward FDA approval of its lead drug candidate, oxylanthanum carbonate (OLC), for treating hyperphosphatemia in dialysis patients. The FDA has assigned a facility inspection to the third-party manufacturer, a prerequisite for NDA resu…
Electra Battery Materials Corporation announced the appointment of Peter Rawlins as its new CFO, effective August 26, 2026, bringing extensive mining finance and capital markets experience. The company reported Q2 2026 financial results showing progress in the construction of North America's first cobalt sulfate refinery in Ontario, with constructi…
Polar Power, Inc. announced $7.9 million in revenue from the Pacific Islands since 2024, driven by 333 shipments of DC power and solar-hybrid systems to countries including Papua New Guinea and Fiji. Repeat orders from telecommunications customers indicate growing adoption and reliability of its technology. The company is now expanding into adjacen…
Milestone Pharmaceuticals announced Q2 2026 financial results and corporate updates, reporting increased patient and prescriber adoption of its FDA-approved cardiovascular drug CARDAMYST for PSVT, expanded insurance coverage to over 50% of commercially insured lives in the U.S., and initiation of a Phase 3 registrational trial for atrial fibrillati…
Kamada Ltd., a global biopharmaceutical company specializing in specialty plasma-derived therapies, announced record-high revenues and adjusted EBITDA for the first half and second quarter of 2026, driven by strong sales growth of its proprietary products like KEDRAB in the U.S., VARIZIG, and HEPAGAM. The company affirmed its 2026 annual financial …
Alterity Therapeutics announced the granting of a new U.S. composition of matter patent for its lead clinical drug candidate ATH434. This patent extends protection until at least 2045, significantly increasing ATH434's commercial value and underpinning the planned initiation of Phase 3 trials in Multiple System Atrophy by the end of 2026. The stren…
StoneX Group Inc., a US-listed financial services company, has agreed to acquire Banco Travelex S.A., Brazil's first bank specialized exclusively in foreign exchange and authorized as a multiple-service bank. This acquisition will expand StoneX's payment and FX capabilities in Brazil, enabling clients to hold local and foreign currency accounts, an…
Acumen Pharmaceuticals reported its Q2 2026 financial results and business updates, highlighting the upcoming topline results from its Phase 2 ALTITUDE-AD study evaluating sabirnetug (ACU193) for early Alzheimer's disease, expected in late 2026. The company nominated two candidates under its Enhanced Brain Delivery (EBD) program with a lead IND fil…
Kornit Digital Ltd. reported second quarter 2026 financial results with total revenues of $55.3 million, surpassing the high end of guidance. The company achieved positive adjusted EBITDA margin, increased Annual Recurring Revenue (ARR) by 79% year-over-year to $33.8 million, and saw All-Inclusive Click (AIC) revenues more than double. Kornit's dig…
Fusemachines Inc. announced a strategic agreement with South American technology services leader Qintess, who has committed to spend at least $6.5 million on Fusemachines' Agentic AI products and services over the next three years. The partnership aims to integrate Fusemachines' AI technology within Qintess' operations and client offerings, expandi…
SUNation Energy reported its Q2 2026 financial results with a 38% year-over-year decline in consolidated revenue primarily due to the expiration of the federal Section 25D residential solar tax credit. The company focused on cost reductions, balance sheet improvements, and progressed a strategic reverse merger transaction with Suniva, Inc., targeti…
Sutro Biopharma announced favorable early clinical activity of STRO-004 in its Phase 1 trial demonstrating partial responses and a good safety profile. The company is rapidly progressing dose optimization and plans to initiate additional clinical trials of STRO-006 and dual-payload ADC STRO-227 in 2026. Sutro reported solid cash reserves of $164.3 …
LeonaBio announced that its lead drug candidate, lasofoxifene, will be highlighted in several presentations at Dava Oncology's 4th Summit on Breast Cancer. The presentations will emphasize lasofoxifene's potential as a novel treatment for ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer, including progress in its pivotal Phase 3 EL…
Auddia Inc. (NASDAQ: AUUD) has filed its definitive proxy statement with the SEC and scheduled a special shareholder meeting on September 23, 2026, to vote on its proposed merger with Thramann Holdings. This merger will create McCarthy Finney, an AI-focused holding company combining Auddia and three AI native companies: LT350, Influence Healthcare,…
